Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2021-07-15
Product name:
NALOXONE HYDROCHLORIDE INJECTION, USP
Description:
PRESERVATIVE-FREE (SINGLE DOSE VIAL)
DIN:
02518066
Product Monograph/Veterinary Labelling:
Date:
2021-07-12
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BAXTER CORPORATION
7125 Mississauga Road
Mississauga
Ontario
Canada
L5N 0C2
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Subcutaneous , Intravenous , Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
28:10.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
V03AB15 NALOXONE
Active ingredient group (AIG) number:See footnote5
0108981002
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| NALOXONE HYDROCHLORIDE | 0.4 MG / ML |